None listed
Conditions
Interventions
None listed
Sponsors
Gachon University Gil Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Subjects who decide to undergo bariatric metabolic surgery - After receiving and understanding a detailed explanation of the pesent clinical study, those who voluntarily decided to participate as research subjects and gave written consent - Adults over 19 years old, under 60 years old - Those who have no serious systemic diseases requiring treatment other than metabolic diseases related to obesity and no pathological symptoms or findings as a result of medical examination. - Those who are determined to be suitable clinical trial subjects as a result of laboratory tests such as medical examination, physical examination, serology test, hematology test, blood chemistry test, and urinalysis after the screening test. - As a normal control group, subjects for laparoscopic surgery for benign abdominal diseases or liver transplant donors
Exclusion criteria
Exclusion criteria: - Persons under 19 years of age and over 60 years of age - Women who are pregnant or planning to become pregnant within one year - Drug abusers - Patients with alcoholic liver disease or other confirmed liver diseases: hepatitis B or C, autoimmune hepatitis, drug-induced liver damage, and other liver diseases - History of taking drugs that cause secondary fatty liver disease within the past 6 months (corticosteroids, tamoxifen, amiodarone, methotrexate, etc.) - Patients with biliary disease or liver disease with confirmed ascites - Patients who have developed cardiovascular or cerebrovascular disease within the past year - Expected glomerular filtration rate <30 ml/min/1.73 meter squared in renal function test - Persons deemed unsuitable for participation in obesity metabolic surgery or clinical research according to the judgment of the research director
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1) Changes in plasma/urine metabolites and metabolism-related variables before and after bariatric surgery; 2) Discovery of progression biomarkers and therapeutic targets for non-alcoholic fatty liver disease through liver tissue omics data and integrated analysis;1) Correlation between gastric mucosal tissue transcriptome and body weight in obese patients; 2) Correlation between gastric mucosal tissue transcriptome and weight change after bariatric surgery in obese patients | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Search for surrogate markers with high correlation with liver fibrosis evaluation variables and correlation with clinical variables; 2) Discovery of plasma/urine biomarkers related to improvement in liver fibrosis | — |
Countries
Korea, Republic of
Contacts
Public ContactDae Ho Lee
Gachon University Gil Medical Center
Outcome results
None listed